A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
A phase 1/2 trial of MK-1045 in non-hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) is a phase 1/2 interventional study registered as NCT07519772 by Merck Sharp & Dohme LLC, with 280 participants planned, started 2026-05-03 and due to reach its primary completion in 2030-07-01. Interventions recorded: MK-1045. Conditions listed: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse. No results are recorded here; the registry entry is the source.
Setting
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma
Phase
Phase 1/2
Sponsor
Merck Sharp & Dohme LLC
Registry
Enrolled
280
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Shares MK-1045, Merck & Co. (MSD).
- TrialA Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Shares MK-1045, Merck & Co. (MSD).
- TrialA Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
- TrialA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).